title: Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages.
abstract: OBJECTIVE
  To explore whether the angiotensin II (Ang II) receptor 1 (AT1) antagonist, losartan could reduce activity and expression of matrix metalloproteinases (MMPs) in rat atherosclerotic plaques.
  
  
  METHODS
  Male Wistar-Kyoto rats were ip injected a single dose of vitamin D3 600 kU x kg(-1) x month(-1) and fed an atherogenic diet for 4 months to induce experimental atheroma. Then either placebo or losartan 50 mg x kg(-1) x d(-1) was administered in rats for another 2 months. In vitro, the effect of losartan 0.1-10 micromol/L on the expression of MMP-2 and MMP-9 was investigated in Ang II-stimulated rat peritoneal macrophages. The expression and activity of MMP-2 and MMP-9 were monitored by Western blot, RT-PCR, and SDS-PAGE zymography analysis.
  
  
  RESULTS
  High levels of MMP-2 and MMP-9 were expressed in rat atherosclerotic lesions. Losartan significantly reduced the activity and expression of MMP-2 and MMP-9 compared with the placebo group (MMP-2, 5861+/-539 vs 8991+/-965, P<0.05; MMP-9,10527+/-1002 vs 14623+/-2462, P<0.01). In cultured rat peritoneal macrophages, Ang II 0.1 micromol/L elicited an increase in MMP-2 and MMP-9 activity and expression that were prevented by losartan in a dose-dependent manner (P<0.01). But the AT2 receptor antagonist PD123319 had no effect.
  
  
  CONCLUSIONS
  Losartan reduced the expression and activity of MMP-2 and MMP-9 in rat atherosclerotic lesions. The anti-atherogenic effects of losartan were due to the direct inhibition of Ang II bioactivity.
authors.affiliation: Department of Cardiology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Chun
authors.initials: C
authors.lastname: Liang
authors.forename: Zong-gui
authors.initials: ZG
authors.lastname: Wu
authors.forename: Jian
authors.initials: J
authors.lastname: Ding
authors.forename: Jian-fei
authors.initials: JF
authors.lastname: Jiang
authors.forename: Gao-zhong
authors.initials: GZ
authors.lastname: Huang
authors.forename: Rong-zeng
authors.initials: RZ
authors.lastname: Du
authors.forename: Jun-bo
authors.initials: JB
authors.lastname: Ge
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis / Q000201:enzymology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D019808:Losartan / Q000494:pharmacology*; D017737:Macrophages, Peritoneal / Q000201:enzymology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis* / Q000235:genetics; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011921:Rats, Inbred WKY
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D012333:RNA, Messenger; D000804:Angiotensin II; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D019808:Losartan